» Articles » PMID: 35884002

Eradication Efficacy of Therapy Based on the Antimicrobial Susceptibility in Children with Gastritis and Peptic Ulcer in Mekong Delta, Vietnam

Overview
Specialty Health Services
Date 2022 Jul 27
PMID 35884002
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The efficacy of () eradication therapy for children is currently low, and antibiotic resistance is a significant cause of treatment failure. The purpose of this study was to evaluate the eradication efficacy of therapy based on antimicrobial susceptibility in pediatric patients with gastritis and peptic ulcer.

Methods: This study was conducted at Can Tho Children's Hospital and Can Tho University of Medicine and Pharmacy Hospital between March 2019 and April 2022. We performed an upper gastrointestinal endoscopy, cultured from biopsies of gastric mucosa, determined antibiotic sensitivities to by the E-test method, and treated eradication based on the antibiotic susceptibilities of bacteria. After at least 4 weeks of eradication therapy, we assessed the effectiveness of treatment with a breath test.

Results: Among 237 children recruited in this study, 48.9% were boys and 51.1% were girls, and the mean age was 10.03 ± 2.53 years. We determined that 80.6% of were resistant to clarithromycin, as well as amoxicillin, metronidazole, levofloxacin, and tetracycline, at 71.7%, 49.4%, 45.1%, and 11.4%, respectively. The overall eradication rate of was 83.1% (172/207). Among therapies tailored to antimicrobial susceptibility, the bismuth quadruple regimen achieved the greatest success, but the efficacy of triple therapy with esomeprazole + AMX + CLR/MTZ was low.

Conclusions: Tailored eradication therapy was highly successful in our study but did not achieve over 90%. We recommend that in countries with a high prevalence of antibiotic resistance in strains, particularly where the amoxicillin-resistance rate of is high, therapy tailored to antimicrobial susceptibility should be used as first-line therapy, and bismuth and tetracycline should be added to enhance the eradication efficacy in children.

Citing Articles

Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis.

Salahi-Niri A, Nabavi-Rad A, Monaghan T, Rokkas T, Doulberis M, Sadeghi A BMC Med. 2024; 22(1):598.

PMID: 39710669 PMC: 11664859. DOI: 10.1186/s12916-024-03816-y.


antibiotic resistance profile in Chinese children with upper gastrointestinal symptoms and a literature review for developing personalized eradicating strategies.

Zhou D, Wang W, Gu L, Han M, Hao W, Huang J Front Pharmacol. 2024; 15:1392787.

PMID: 38887553 PMC: 11180794. DOI: 10.3389/fphar.2024.1392787.


A Survey of Pharmacists and Other Healthcare Professionals in Vietnam: Factors Influencing Knowledge and Attitudes Toward Reporting Adverse Drug Reactions.

De Tran V, Tran T, Vo Q, Pham K, Dewey R, Van C Hosp Pharm. 2024; 59(1):56-69.

PMID: 38223867 PMC: 10786064. DOI: 10.1177/00185787231186506.


Infections in Children.

Nguyen J, Kotilea K, Bontems P, Miendje Deyi V Antibiotics (Basel). 2023; 12(9).

PMID: 37760736 PMC: 10525885. DOI: 10.3390/antibiotics12091440.


Paediatric gastrointestinal endoscopy in the Asian-Pacific region: Recent advances in diagnostic and therapeutic techniques.

Huang J, Tanpowpong P World J Gastroenterol. 2023; 29(18):2717-2732.

PMID: 37274071 PMC: 10237107. DOI: 10.3748/wjg.v29.i18.2717.


References
1.
Van Thieu H, Duc N, Nghi B, Van Bach N, Khoi H, Tien V . Antimicrobial Resistance and the Successful Eradication of -Induced Gastroduodenal Ulcers in Vietnamese Children. Med Arch. 2021; 75(2):112-115. PMC: 8228587. DOI: 10.5455/medarh.2021.75.112-115. View

2.
Zhang Y, Dong Q, Zhang S, Gu F, Zhang Y, Song H . [Effectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory infection]. Zhonghua Er Ke Za Zhi. 2020; 58(1):41-45. DOI: 10.3760/cma.j.issn.0578-1310.2020.01.010. View

3.
Quach D, Vilaichone R, Vu K, Yamaoka Y, Sugano K, Mahachai V . Helicobacter pylori Infection and Related Gastrointestinal Diseases in Southeast Asian Countries: An Expert Opinion Survey. Asian Pac J Cancer Prev. 2018; 19(12):3565-3569. PMC: 6428556. DOI: 10.31557/APJCP.2018.19.12.3565. View

4.
Lima J, Thomas C, Barbarino J, Desta Z, Van Driest S, El Rouby N . Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2020; 109(6):1417-1423. PMC: 7868475. DOI: 10.1002/cpt.2015. View

5.
Shah S, Iyer P, Moss S . AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology. 2021; 160(5):1831-1841. PMC: 8281326. DOI: 10.1053/j.gastro.2020.11.059. View